Rappta Therapeutics is pioneering a novel approach in cancer treatment through its development of first-in-class anti-cancer molecular glues that specifically target and reactivate the tumor suppressor protein phosphatase 2A (PP2A). This critical enzyme plays a significant role in regulating protein de-phosphorylation and tumor growth, making it a vital target in the fight against various cancers. The company has leveraged its proprietary tools and deep understanding of PP2A biology to create small molecule compounds that facilitate the reformation of the PP2A complex, allowing it to effectively bind to oncogenic substrates. This innovative strategy aims to address the challenges associated with targeting PP2A pharmaceutically, which has historically been difficult.

The scientific team at Rappta Therapeutics comprises leading experts in PP2A research, who have contributed extensively to the understanding of its chemistry and biology. By solving the high-resolution structure of the PP2A-drug complex, the team has been able to develop a series of compounds that enhance the tumor-suppressive functions of PP2A. This platform technology not only holds promise for treating a wide range of cancers but also has potential applications in addressing other diseases characterized by protein hyperphosphorylation, such as neurodegenerative disorders. Through this innovative approach, Rappta Therapeutics aims to redefine cancer therapeutics and improve patient outcomes.

Finland

Rappta Therapeutics is a late pre-clincal stage biopharmaceutical company
We are working on a first-in-class series of anti-cancer molecular glues that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A). Rappta’s proprietary tools and understanding of the target allow us to therapeutically reactivate PP2A, a critical enzyme regulating protein de-phosphorylation and tumor growth. As a result of PP2A’s central role in the regulation of protein phosphorylation, Rappta’s PP2A-reactivating technologies have platform potential for treating a broad range of human diseases.

Rappta Therapeutics

Company Details